Skip to main content

Table 1 Clinical and demographic characteristics of test and validation cohorts

From: Small RNA sequencing of extracellular vesicles identifies circulating miRNAs related to inflammation and oxidative stress in HIV patients

  Test cohort Validation cohort
  HIV-negative (n = 12) HIV-positive (n = 12) HIV-negative (n = 8) HIV-positive (n = 8)
Ageα 52 [44–59] 55 [45–60] 53 [51–54] 57 [53–61]
Black race 7 (58) 8 (67) 3 (38) 3 (38)
Male gender 12 (100) 12 (100) 3 (38) 7 (88)
Duration of HIV infection (years)α   13 [11–20]   19 [13–22]
Viral load (copies/ml)   40 [10–80]   40 [40–40]
Viral load < 200 copies/ml   11 (92)   8 (100)
CD4 count (cells/μl) 955 [776–1142] 619 [430–734]   382 [285–495]
CD4 nadir (cells/μl) 639 [539–796] 166 [92–257]   82 [26–221]
CD4/CD8 ratioα 1.4 [1.1–1.9] 0.73 [0.54–1.0]   0.41 [0.26–0.51]
ART use   12 (100)   8 (100)
Protease inhibitor use   7 (58)   6 (75)
HCV seropositive 1 (8) 1 (8) 0 (0) 0 (0)
Smoking 7 (58) 6 (50) 7 (88) 2 (25)
Cocaine use 6 (50) 6 (50) 4 (50) 4 (50)
  1. Data shown are n (%) unless otherwise indicated
  2. α median [IQR]